公开(公告)号：EP2632468A1

公开(公告)日：2013-09-04

申请号：EP11835385.3

申请日：2011-10-24

申请人： University Of Manitoba

发明人： FERNYHOUGH, Paul ,  CALCUTT, Nigel, A. ,  KOTRA, Lakshmi

IPC分类号： A61K31/5513 ,  A61K31/46 ,  A61K31/496 ,  A61P25/02 ,  C07D417/12 ,  C07D451/10 ,  C07D471/04 ,  C07D495/04

CPC分类号： A61K31/5513 ,  A61K31/46 ,  A61K31/496 ,  C07D417/12

摘要： Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.

摘要翻译： 用于治疗有需要的受试者的糖尿病性对称性多发性神经病的组合物，所述组合物包含：有效量的吡罗西泮，替硝西泮，阿托品或其衍生物或其盐或其类似物或其衍生物所示的毒蕈碱性乙酰胆碱受体拮抗剂，和 药理学上可接受的载体。 组合物可以是可注射的或者可替换地，可以局部施用或者可以口服施用。 合适的局部组合物可以包含洗剂，霜剂，凝胶或粘稠流体。 毒蕈碱性乙酰胆碱受体拮抗剂可以是毒蕈碱性乙酰胆碱受体拮抗剂盐或毒蕈碱性乙酰胆碱受体拮抗剂衍生物或毒蕈碱性乙酰胆碱受体拮抗剂类似物。

公开(公告)号：EP3363439A2

公开(公告)日：2018-08-22

申请号：EP17206278.8

申请日：2011-10-24

申请人： University Of Manitoba

发明人： FERNYHOUGH, Paul ,  CALCUTT, Nigel A. ,  KOTRA, Lakshmi

IPC分类号： A61K31/5513 ,  A61K31/46 ,  A61K31/496 ,  A61P25/02 ,  C07D417/12 ,  C07D451/10 ,  C07D471/04 ,  C07D495/04

CPC分类号： A61K31/5513 ,  A61K31/46 ,  A61K31/496 ,  C07D417/12

摘要： Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.

公开(公告)号：EP3363439A3

公开(公告)日：2018-12-05

申请号：EP17206278.8

申请日：2011-10-24

申请人： University Of Manitoba

发明人： FERNYHOUGH, Paul ,  CALCUTT, Nigel A. ,  KOTRA, Lakshmi

IPC分类号： A61K31/5513 ,  A61K31/46 ,  A61K31/496 ,  A61P25/02 ,  C07D417/12 ,  C07D451/10 ,  C07D471/04 ,  C07D495/04

CPC分类号： A61K31/5513 ,  A61K31/46 ,  A61K31/496 ,  C07D417/12

摘要： Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.

公开(公告)号：EP2632468B1

公开(公告)日：2017-12-13

申请号：EP11835385.3

申请日：2011-10-24

申请人： University Of Manitoba

发明人： FERNYHOUGH, Paul ,  CALCUTT, Nigel, A. ,  KOTRA, Lakshmi

IPC分类号： A61K31/5513 ,  A61K31/46 ,  A61K31/496 ,  A61P25/02 ,  C07D417/12 ,  C07D451/10 ,  C07D471/04 ,  C07D495/04

CPC分类号： A61K31/5513 ,  A61K31/46 ,  A61K31/496 ,  C07D417/12

摘要： Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.